Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vecabrutinib - Sunesis Pharmaceuticals

Drug Profile

Vecabrutinib - Sunesis Pharmaceuticals

Alternative Names: SNS 062; SNS-062-succinate

Latest Information Update: 03 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec; Sunesis Pharmaceuticals
  • Developer Biogen; Sunesis Pharmaceuticals
  • Class Amides; Antineoplastics; Piperidines; Pyrimidines; Small molecules; Succinates
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Haematological malignancies

Most Recent Events

  • 15 Jun 2019 Efficacy, pharmacokinetics, pharmacodynamics and adverse events data from a phase I/II trial in Haematological malignancies released by Sunesis Pharmaceuticals
  • 13 Jun 2019 Updated efficacy, adverse events, pharmacodynamics and pharmacokinetics data from a phase I/II trial in Haematological malignancies presented at the 24th Congress of the European Haematology Association (EHA-2019)
  • 28 Apr 2019 No recent reports of development identified for phase-I development in Haematological-malignancies in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top